The burden of chronic diseases and cost-of-care in subjects with HIV infection in a Health District of Northern Italy over a 12-year period compared to that of the general population

BMC Public Health

Volumn 16, Issue 1, 2016, Pages 1-10

  Quiros Roldan, Eugenia ^a   Magoni, Michele ^b   Raffetti, Elena ^c   Donato, Francesco ^c   Scarcella, Carmelo ^b   Paraninfo, Giuseppe ^a   Castelli, Francesco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Brescia Local Health Authority   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Burden of HIV; Chronic diseases; Cost for HIV care; Prevalence

Indexed keywords

ADULT; CHRONIC DISEASE; COMORBIDITY; COMPARATIVE STUDY; COST OF ILLNESS; DRUG COST; ECONOMICS; FEMALE; HEALTH CARE COST; HIV INFECTIONS; HUMAN; INCIDENCE; ITALY; MALE; MIDDLE AGED; PATIENT ATTITUDE; PREVALENCE; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; CHRONIC DISEASE; COMORBIDITY; COST OF ILLNESS; DRUG COSTS; FEMALE; HEALTH EXPENDITURES; HIV INFECTIONS; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PREVALENCE; PUBLIC HEALTH;

EID: 84994719653     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-016-3804-4     Document Type: Article

References (40)

1. Raffetti E, Albini L, Gotti D, et al. Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study. BMC Public Health. 2015;15:235. doi:10.1186/s12889-015-1565-0.
2. Helleberg M, Kronborg G, Larsen CS, et al. Causes of death among Danish HIV patients compared with population controls in the period 1995-2008. Infection. 2012;40(6):627-34.
3. Grinsztejn B, Luz PM, Pacheco AG, et al. Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era. PLoS One. 2013;8(4), e59768.
4. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241-8.
5. Bayoumi AM, Barnett PG, Joyce VR, et al. Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease. J Acquir Immune Defic Syndr. 2013;64(4):382-91.
6. Tontodonati M, Cenderello G, Celesia BM, et al. Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. Clinicoecon Outcomes Res. 2014;7:27-35. doi:10.2147/CEOR.S69183. eCollection 2015.
7. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9.
8. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8(12), e81355.
9. Guaraldi G, Zona S, Menozzi M, et al. Cost of noninfectious comorbidities in patients with HIV. Clinicoecon Outcomes Res. 2013;5:481-8. doi:10.2147/CEOR.S40607.
10. Magoni M, Scarcella C, Vassallo F, et al. The evolving burden of HIV infection compared with other chronic diseases in northern Italy. HIV Med. 2011;12(3):129-37. doi:10.1111/j.1468-1293.2010.00861.x.
11. HIV/AIDS Italian Expert Panel. (2015). Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. Available at: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2442_allegato.pdf. (Accessed 10 Feb 2016).
12. Lombardy Region. Social and Health Care Plan. No 937/2010. Milan: Lombardy Region; 2010. Italian. Available at: http://www.sanita.regione.lombardia.it/shared/ccurl/956/366/DGRregole_e_allegati.zip. (Accessed 10 Feb 2016).
13. Guidelines for ATC classification and DDD assignment, 5th edition. WHO Collaborating Centre for Drug Statistic Methodology, Oslo 2002. Available at www.whocc.no/atcddd. (Accessed 28 Feb 2016).
14. Goldman DP, Juday T, Seekins D, Linthicum MT, Romley JA. Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009. Health Aff (Millwood). 2014;33(3):362-9. doi:10.1377/hlthaff.2013.0830.
15. Dieffenbach CW, Fauci AS. Thirty years of HIV and AIDS: future challenges and opportunities. Ann Intern Med. 2011;154:766-71.
16. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397-404. doi:10.1097/QAD.0b013e32832b7dca.
17. Trapero-Bertran M, Oliva-Moreno J. Economic impact of HIV/AIDS: a systematic review in five European countries. Health Econ Rev. 2014;4(1):15. doi:10.1186/s13561-014-0015-5. Epub 2014 Sep 16.
18. Phillips AN, Cambiano V, Miners A, et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis. Lancet HIV. 2014;1(2):e85-93. doi:10.1016/S2352-3018(14)70021-9. Epub 2014 Oct 14.
19. Mostardt S, Hanhoff N, Wasem J, et al. Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study. Eur J Health Econ. 2013;14(5):799-808. doi:10.1007/s10198-012-0425-4. Epub 2012 Sep 19.
20. Barnett PG, Chow A, Joyce VR, et al. Effect of management strategies and clinical status on costs of care for advanced HIV. Am J Manag Care. 2014;20(5):e129-37.
21. Lombardy Region. Approvazione del documento avente per oggetto Percorso Diagnostico Terapeutico (PDT) per il paziente affetto da malattia HIV/AIDS [Therapeutic and diagnostic path (PDT) for the patient with HIV/AIDS disease]. Decree no 7485, August 5, 2011. Milan: Lombardy Region; 2012. Italian. Available at:http://www.sanita.regione.lombardia.it/cs/Satellite?c=Page&childpagename=DG_Sanita/Page/NormativaDetail&pagename=DG_SANWrapper&cid=1213275902673&keyid=3520. (Accessed 10 Feb 2016).
22. Krentz HB, Gill MJ. Increased costs of HIV care associated with aging in an HIV-infected population. HIV Med. 2015;16(1):38-47. doi:10.1111/hiv.12176. Epub 2014 Aug 8.
23. Braithwaite RS, Justice AC, Chang CC, et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Am J Med. 2005;118(8):890-8.
24. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53(11):1120-6. doi:10.1093/cid/cir627. Epub 2011 Oct 13.
25. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-55.
26. Towner WJ, Xu L, Leyden WA, et al. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr. 2012;60(3):321-7.
27. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;116(22):5306-15.
28. Cutrell J, Bedimo R. Non-AIDS-defining cancers among HIV-infected patients. Curr HIV/AIDS Rep. 2013;10(3):207-16.
29. Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016;3(1):e23-32. doi:10.1016/S2352-3018(15)00211-8. Epub 2015 Nov 17.
30. Longenecker CT, Triant VA. Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease? Curr Opin HIV AIDS. 2014;9(1):54-62.
31. Torti C, Raffetti E, Donato F, et al. Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). Int J Epidemiol 2015 Oct 7. [Epub ahead of print] No abstract available. PMID: 26445966.
32. Fedeli U, Schievano E, Lisiero M, Avossa F, Mastrangelo G, Saugo M. Descriptive epidemiology of chronic liver disease in northeastern Italy: an analysis of multiple causes of death. Popul Health Metr. 2013;11(1):20. doi:10.1186/1478-7954-11-20.
33. Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol. 2005;75(4):522-7.
34. Fleishman JA, Yehia BR, Moore RD, Gebo KA. HIV Research Network. The economic burden of late entry into medical care for patients with HIV infection. Med Care. 2010;48(12):1071-9. doi:10.1097/MLR.0b013e3181f81c4a.
35. Krentz HB, Gill MJ. The Direct Medical Costs of Late Presentation (<350/mm) of HIV Infection over a 15-Year Period. AIDS Res Treat. 2012;2012:757135. doi:10.1155/2012/757135. Epub 2011 Aug 29.
36. Rizzardini G, Restelli U, Bonfanti P, et al. Cost of human immunodeficiency virus infection in Italy, 2007-2009: effective and expensive, are the new drugs worthwhile? Clinicoecon Outcomes Res. 2012;4:245-52.
37. Calabresi A, Ferraresi A, Festa A, et al. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009. HIV Med. 2013;14(8):481-90. doi:10.1111/hiv.12034. Epub 2013 Apr 7.
38. Lonati F, Scarcella C, Indelicato A, et al. Brescia Local Health Autority Population Database: a method based on current data for monitoring chronic diseases and management. Epidemiol Prev. 2008;32(3):137-44. Italian.
39. Notiziari ISS che riportano i dati italiani su HIV/AIDS, http://www.iss.it/ccoa/?lang=1&id=2&tipo=5. (Accessed 26 Aug 2016).
40. Average Annual Inflation Rate, http://www.re.camcom.gov.it/Sezione.jsp?idSezione=753. (Accessed 17 Apr 2016).